Offer subject to change or discontinuance without notice. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Program provides for RINVOQ® (upadacitinib) at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Patients must have a valid prescription for RINVOQ® (upadacitinib) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. ‡ Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. For full Terms and Conditions, visit for RINVOQ® patients, and for HUMIRA® patients, or call 1.8‍0‍0.2‍RINVOQ or 1.8‍0‍0.4‍HUMIRA for additional information To learn about AbbVie’s privacy practices and your privacy choices, visit Restrictions, including monthly maximums, may apply. Offer subject to change or termination without notice. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. †Eligibility: Available to patients with commercial insurance coverage for RINVOQ® (upadacitinib), or HUMIRA® (adalimumab) who meet eligibility criteria. They are trained to direct patients to speak with their HCP about any treatment‑related questions, including further referrals. *Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP).

Humira copay card group number